The generic product names are the same; only the brand names are changing. Studies show no differences between products, and dosing and monitoring remain the same for both replaced products 

The new insulin products are: 

• Basal insulin 

• Insulin glargine: Semgless will replace Lantus  

• Rapid-acting insulin 

• Insulin lispro: Admelog will replace Humalog

New Speed Buttons in Discontinue Prescription Window (Outpatient) 

Beginning March 3, new speed buttons will appear in the Discontinue Prescription window in the outpatient setting. The new buttons allow clinicians to indicate if a stopped medication should appear on after visit summary (AVS). The new buttons are: 

• Stopped – on AVS 

• Cleanup – not on AVS 

Refer to Tip Sheet “Customizing Outpatient Medication Discontinue Reasons” (available in Hubbl) for more information